PolyPid Ltd.

2.55
0.04 (1.51%)
At close: Apr 10, 2025, 3:56 PM
2.51
-1.59%
After-hours: Apr 10, 2025, 04:12 PM EDT

Company Description

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs.

Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PolyPid Ltd.
PolyPid Ltd. logo
Country IL
IPO Date Jun 26, 2020
Industry Biotechnology
Sector Healthcare
Employees 57
CEO Dikla Czaczkes Akselbrad

Contact Details

Address:
18 Hasivim Street
Petah Tikva,
IL
Website https://www.polypid.com

Stock Details

Ticker Symbol PYPD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001611842
CUSIP Number M8001Q118
ISIN Number IL0011326795
Employer ID 00-0000000
SIC Code 3841

Key Executives

Name Position
Dalit Hazan Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs
Dikla Czaczkes Akselbrad Chief Executive Officer & Director
Jonny Missulawin Chief Financial Officer
Ori Warshavsky Chief Operating Officer - US
Dr. Jean-Marc Hagai Pharm.D. Chief Commercial Officer
Maria Rubin Executive Vice President of Operations
Rivi Lev-ari Vice President of Human Resource
Tal Vilnai General Counsel & Corporate Secretary

Latest SEC Filings

Date Type Title
Apr 03, 2025 SCHEDULE 13G/A [Amend] Filing
Mar 11, 2025 6-K Filing
Feb 26, 2025 20-F Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 12, 2025 6-K Filing
Feb 10, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 21, 2025 F-3 Filing
Jan 17, 2025 6-K Filing
Jan 02, 2025 D Filing